DNA profiling definition

DNA profiling means the procedure established by
Sample 1Sample 2Sample 3
DNA profiling means the procedure for determining a person’s genetic identity or for testing a forensic sample, including analysis that might not result in the establishment of a complete DNA profile.
Sample 1Sample 2Sample 3
DNA profiling means the procedure established by the division of criminal investigation, department of public safety, for determining a person’s genetic identity.
Sample 1Sample 2Sample 3

Examples of DNA profiling in a sentence

  • Wilson, BSc, MSc, PhD (McMaster), evolutionary genetics, DNA profiling (Canada Research Chair in DNA Profiling, Forensics, and Functional Genomics)M.

  • For DNA profiling of plant varieties and database construction, molecular markers should be selected according to the objective.

  • The following is a summary of the approach recommended for high quality DNA profiling of varieties including the selection and use of molecular markers as well as the construction of shared and sustainable molecular databases (i.e. databases that can be populated in the future with data from a range of sources, independent of the technology used).

  • The laboratory will examine evidence for human biological samples and characterize the samples using DNA technologies.150.3(5) DNA profiling.

  • The most recent advances in Automated Fingerprint Identification Systems (AFIS), rapid DNA profiling devices, drugs analysers and digital- device data-recovery kiosks provide the prospect of ‘real-time forensics’ that will change not only the forensic operating model but the policing and investigative models.

  • Our long‐held idea that inno‐ cent people do not confess to crimes has been upended by advances in DNA profiling.

  • This module is essential for you to place DNA profiling results in the correct context for interpretation and presentation in reports or in court through testimony.

  • As powerful as DNA profiling has become in its sensitivity and power to discriminate individuals, the major challenge today is to identify the DNA of the criminal against a background of DNA fromFORENSIC SCIENCE IN PRACTICE the victim, or a range of other individuals who may have visited the location of the crime.

  • To do this, a judge or jury needs to apply some sort of rational reasoning in order to draw conclusions from the evidence about what may have happened.With the rise of modern forensic techniques such as DNA profiling, a judge or jury is now faced with the task of reasoning about pieces of evidence that come with some quantified uncertainty.

  • Site directed mutagenesis, Ribonuclease protection assay, Gel retardation assay, DNA foot printing, DNA finger printing, DNA profiling, Genomic analysis: Exon-intron trapping, S-1 mapping, RFLP, RAPD, AFLP.


More Definitions of DNA profiling

DNA profiling means the procedure established
Sample 1Sample 2
DNA profiling means the procedure established by the division of criminal investiga- tion, department of public safety, for determining a person’s genetic identity.
Sample 1

Related to DNA profiling

  • DNA profile means a letter or number code which represents a set of identification characteristics of the non-coding part of an analysed human DNA sample, i.e. the particular molecular structure at the various DNA locations (loci);

  • DRS/Profile means the system for the uncertificated registration of ownership of securities pursuant to which ownership of ADSs is maintained on the books of the Depositary without the issuance of a physical certificate and transfer instructions may be given to allow for the automated transfer of ownership between the books of DTC and the Depositary. Ownership of ADSs held in DRS/Profile is evidenced by periodic statements issued by the Depositary to the Holders entitled thereto.

  • Profiling means any form of automated processing of personal data consisting of the use of personal data to evaluate certain personal aspects relating to a natural person, in particular to analyse or predict aspects concerning that natural person's performance at work, economic situation, health, personal preferences, interests, reliability, behaviour, location or movements;

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Dose profile means the dose as a function of position along a line.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Research Program has the meaning set forth in Section 3.1.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Development Program means the implementation of the development plan.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Collaboration has the meaning set forth in Section 2.1.

  • Collaborating physician means the physician who,

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.